Werner Milton H. — SEC Form 4 filings

SEC reporting owner CIK 1827621. 3 Form 4 filings on record with FilingPulse; latest filed 2025-01-22.

Transaction summary — filings shown

Covers all 3 filings on record, filed 2024-04-03 to 2025-01-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Inhibikase Therapeutics, Inc. (IKT)President and CEO, Director322

Form 4 filings — Werner Milton H.

FiledFormIssuerReported transactionsSource
2025-01-224Inhibikase Therapeutics, Inc. (IKT)Disposition to issuer (D): 3,643 (derivative) @ $0 · Grant/award (A): 3,643 (derivative) @ $0 · Disposition to issuer (D): 3,643 (derivative) @ $0 · Grant/award (A): 3,643 (derivative) @ $0 · Disposition to issuer (D): 3,643 (derivative) @ $0 · Grant/award (A): 3,643 (derivative) @ $0 · +12 moreEDGAR
2025-01-074Inhibikase Therapeutics, Inc. (IKT)Grant/award (A): 5,315,056 (derivative) @ $0 · Grant/award (A): 2,207,671 (derivative) @ $0 · Grant/award (A): 4,059,744 (derivative) @ $0EDGAR
2024-04-034Inhibikase Therapeutics, Inc. (IKT)Grant/award (A): 45,000 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1827621 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →